Gemmer Asset Management LLC Biogen Inc. Transaction History

Gemmer Asset Management LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 22, 2022	SELL	$187.54 - $223.02 $35,445 - $42,150	-189 Closed	0 $0
Q1 2022 Apr 20, 2022	SELL	$193.77 - $244.14 $193 - $244	-1 Reduced 0.53%	189 $39,000
Q4 2021 Jan 21, 2022	SELL	$223.92 - $287.77 $2,239 - $2,877	-10 Reduced 5.0%	190 $46,000
Q3 2021 Oct 19, 2021	BUY	$282.99 - $369.05 $3,112 - $4,059	11 Added 5.82%	200 $57,000
Q2 2021 Jul 23, 2021	BUY	$259.0 - $414.71 $777 - $1,244	3 Added 1.61%	189 $65,000
Q4 2020 Jan 28, 2021	SELL	$236.26 - $355.63 $236 - $355	-1 Reduced 0.53%	186 $46,000
Q3 2020 Oct 21, 2020	BUY	$264.77 - $305.71 $264 - $305	1 Added 0.54%	187 $53,000
Q4 2019 Jan 17, 2020	SELL	$220.06 - $304.07 $440 - $608	-2 Reduced 1.06%	186 $55,000
Q3 2019 Oct 11, 2019	BUY	$217.44 - $243.88 $434 - $487	2 Added 1.08%	188 $44,000
Q2 2019 Jul 18, 2019	SELL	$219.29 - $241.72 $657 - $725	-3 Reduced 1.59%	186 $43,000
Q1 2018 May 11, 2018	SELL	$260.13 - $367.91 $10,405 - $14,716	-40 Reduced 17.47%	189 $52,000
Q4 2017 Jan 16, 2018	BUY	$307.64 - $344.58 $12,305 - $13,783	40 Added 21.16%	229 $73,000
Q3 2017 Oct 12, 2017	BUY	$281.15 - $329.69 $53,137 - $62,311	189	189 $59,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Gemmer Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Gemmer Asset Management LLC with notifications on news.